HSIC
Henry Schein Inc
NASDAQ: HSIC · HEALTHCARE · MEDICAL DISTRIBUTION
$68.99
+1.51% today
Updated 2026-06-05
Market cap
$9.26B
P/E ratio
24.55
P/S ratio
0.69x
EPS (TTM)
$3.31
Dividend yield
—
52W range
$62 – $89
Volume
1.4M
WallStSmart proprietary scores
52
out of 100
Grade: C
Hold
Investment rating
4.7
Growth
C5.0
Quality
C+5.5
Profitability
C+6.7
Valuation
B2/9
Piotroski F-Score
Weak
2.4
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$88.07
+27.66%
12-Month target
$74.13
+7.45%
Intrinsic (DCF)
$153.40
Margin of safety
+46.75%
4 Strong Buy4 Buy7 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ 46.75% below intrinsic value
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 2.95%
- Negative free cash flow $-136.00M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $12.65B | $12.34B | $12.67B | $13.18B | $13.38B |
| Net income | $538.00M | $416.00M | $390.00M | $398.00M | $107.00M |
| EPS | — | — | — | — | $3.31 |
| Free cash flow | $506.00M | $353.00M | $661.00M | $573.00M | $-136.00M |
| Profit margin | 4.25% | 3.37% | 3.08% | 3.02% | 2.95% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-26 | BERGMAN, STANLEY M | Sale | 50 | — |
| 2026-05-21 | BERGMAN, STANLEY M | Sale | 50 | — |
| 2026-05-19 | BERGMAN, STANLEY M | Sale | 1,040 | — |
Peer comparison
Smart narrative
Henry Schein Inc trades at $68.99. representing a P/E of 24.55x trailing earnings. Our Smart Value Score of 52/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.37, it sits in the grey zone. TTM revenue stands at $13.38B. with profit margins at 2.95%. Our DCF model estimates intrinsic value at $153.40.
Frequently asked questions
What is Henry Schein Inc's stock price?
Henry Schein Inc (HSIC) trades at $68.99, on a P/E of 24.6x and a P/S of 0.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Henry Schein Inc overvalued?
Henry Schein Inc carries a Smart Value Score of 52/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $153.40 versus the $68.99 price, a 46.8% margin of safety on a cash flow basis.
What is the price target of Henry Schein Inc (HSIC)?
The 12-month analyst consensus target is $88.07, about 27.7% above the current $68.99. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Henry Schein Inc (HSIC)?
Our DCF model estimates intrinsic value at $153.40, a +46.8% margin of safety versus today's $68.99. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Henry Schein Inc's revenue?
Henry Schein Inc's trailing twelve-month revenue is $13.38B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Henry Schein Inc's Altman Z-Score is 2.37, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DISTRIBUTION
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.69x
ROE12.09%
Beta0.82
50D MA$75.32
200D MA$73.43
Shares out0.11B
Float0.09B
Short ratio—
Avg volume1.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—